Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with NarcolepsyGlobeNewsWire • 12/17/19
Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress™ (AV001), a Cysteine Hydrochloride Injection for Treating Neonate Patients Requiring Total Parental Nutrition (TPN)GlobeNewsWire • 12/16/19
Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218GlobeNewsWire • 12/02/19
Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with NarcolepsyGlobeNewsWire • 11/25/19
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/12/19
Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25thGlobeNewsWire • 09/24/19
Avadel Pharma shares soar 22% premarket after FDA cuts sample size in trial of narcolepsy treatmentMarket Watch • 09/23/19
Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25thGlobeNewsWire • 09/18/19
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24thGlobeNewsWire • 09/17/19
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/09/19
Avadel Pharmaceuticals' Promising FT218 Trial Offsets Decline In Its Legacy BusinessSeeking Alpha • 07/09/19
Avadel Pharmaceuticals (AVDL) Interim CEO Greg Divis on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/08/19
Avadel Pharmaceuticals (AVDL) CEO Greg Divis on Q4 2018 Results - Earnings Call TranscriptSeeking Alpha • 03/15/19